APYX

Apyx Medical Corp (APYX) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Apyx Medical Corporation is a surgical aesthetics company focused on Helium Plasma Platform Technology products, including Renuvion, J-Plasma, and the newly launched AYON Body Contouring System. The company operates two primary segments: Surgical Aesthetics and OEM (Original Equipment Manufacturer). In Q3 2025, the company commenced the commercial launch of the AYON system following FDA 510(k) clearance received in May 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Q3 2025 revenue increased 12.1% year-over-year, driven by a 19.1% increase in the Surgical Aesthetics segment due to the commercial launch of AYON and higher handpiece volume. Conversely, the OEM segment declined 17.6% due to lower sales volume to existing customers.
• Margin Expansion: Gross margin improved to 64.4% in Q3 2025 from 60.5% in the prior year, attributed to a favorable product mix (higher percentage of Surgical Aesthetics sales) and geographic mix (higher domestic sales).
• Expense Reduction: Significant cost-cutting measures implemented in late 2024 (including a ~25% workforce reduction) resulted in a 27.5% decrease in salaries and related costs and a 38.7% decrease in R&D expenses for the nine months ended September 30, 2025.
• Loss Narrowing: Net loss attributable to stockholders decreased significantly to $1.98 million in Q3 2025 compared to $4.70 million in Q3 2024.

Guidance, Outlook, and Risks

• Outlook: Management anticipates recurring net losses and cash outflows to continue in the near term. The company aims to achieve cash-flow breakeven through cost savings, targeting annual operating expenses below $40 million in fiscal 2025.
• Product Pipeline: The company submitted a 510(k) premarket notification in October 2025 to expand the AYON label to include power liposuction.
• Liquidity: The company holds $25.1 million in cash. It must maintain a minimum cash balance of $3.0 million to comply with its Perceptive Credit Agreement. Additional financing may be required, which could result in dilution or restrictive covenants.
• Risks:
  • Debt Covenants: Compliance with the Perceptive Credit Agreement depends on meeting revenue targets ($37.0M for 2025) and operating expense limits ($40.0M for 2025).
  • Litigation: The company faces product liability lawsuits regarding Renuvion. While management believes defenses are meritorious, potential losses range from $1.3 million to $1.95 million for specific cases, with additional exposure if insurance deductibles are exceeded.
  • Market Factors: The rise of GLP-1 weight loss drugs initially impacted plastic surgery volumes, though management views this as a potential tailwind for body contouring procedures addressing loose skin.

Investor Verification Checklist

• Verify the trajectory of AYON sales adoption in Q4 2025 to ensure it offsets declines in generator sales and OEM revenue.
• Monitor compliance with Perceptive Credit Agreement covenants, specifically the $37.0M revenue target and $40.0M operating expense cap for 2025.
• Review updates on product liability litigation outcomes and insurance coverage status, as potential losses could materially impact financial condition.
• Assess the impact of GLP-1 drug usage on long-term demand for body contouring procedures versus the initial negative impact on procedure volumes.
• Track cash burn rate relative to the $25.1 million cash balance to determine the runway before additional financing is required.